Med Ed 101

SEPTEMBER 22, 2024

Fluctuations in blood sugars can be very distressing for patients. This is especially true in patients who have adequate control of their diabetes. Adverse effects can lead to an escalation of diabetes medication. I’ll share my top 5 drugs that cause hyperglycemia and ultimately contribute to the prescribing cascade. Corticosteroids The first medication I have […] The post Top 5 Drugs That Cause Hyperglycemia appeared first on Med Ed 101.

Diabetes 80

Diabetes 80

pharmaphorum

SEPTEMBER 22, 2024

FTC lawsuit accuses top three PBMs of using a perverse drug rebate system to artificially inflate the price of insulin products and their profits

69

69

Pharmacy Joe

SEPTEMBER 22, 2024

In this episode, I’ll discuss whether there is a benefit from switching to dexmedetomidine when sedation is started with midazolam. Episode 959: Is there a benefit from switching to dexmedetomidine when sedation is started with midazolam? Subscribe on iTunes , Android , or Stitcher Sedation guidelines recommend light sedation with a non-benzodiazepine agent such as dexmedetomidine or propofol.

Inpatient 52

Inpatient Hospitals 52

Pharmacy Times

SEPTEMBER 22, 2024

The researchers estimate that pregnancy losses because of malaria and parasitemia risk before conception was reduced by 65% to 86%.

Vaccines 45

Vaccines 45

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

FDA Law Blog: Biosimilars

SEPTEMBER 22, 2024

By Steven J. Gonzalez & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — On August 22, 2024, FDA hosted a webinar to provide further guidance on the regulatory requirements it intends to apply to Laboratory Developed Test (LDT) developers in Stage 1 of the phaseout policy of the LDT Final Rule – during which FDA has said laboratories developing LDTs will need to comply with Medical Device Reporting (MDR) (21 CFR Part 803), Corrections and Removals (21 CFR Part 806), and Complaint

Labelling 64

Labelling Communication 64